At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 75 enrolled
Drug / intervention
Posaconazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection
In Brief
A Phase 4 clinical trial evaluating Posaconazole for Fungal Infection and 2 related conditions. Completed, enrolled 75 participants.
Detailed Summary
The purpose of this study is: to explore the potential for different dosing strategies of posaconazole oral suspension (POS) to increase plasma levels and to profile the pharmacokinetics of these dosing strategies in patients with compromised gastrointestinal function and at high risk for Invasive Fungal Infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFungal Infection, Acute Myelogenous Leukemia, Neutropenia
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedMay 2008
Primary CompletionApr 2009
TodayJul 2026
First PostedMay 30, 2008
Enrollment StartDec 1, 2007
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.1 years ago
Interventions
Posaconazoledrug
Posaconazole will be used for prophylaxis